Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl fumarate for mild cognitive impairment and Alzheimer's disease
2022-002171-11Phase 2Active
- Sponsor
- Medical University of Lodz
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mild cognitive impairment due to Alzheimer's disease and Alzheimer's disease (AD) comparing Dimethyl fumarate with Placebo (2 arms). Primary endpoint: Change in cognitive function based on RBANS. Started Oct 2022; status: active.
02
Drugs
dimethyl fumarate
03
Conditions
mild cognitive impairment due to Alzheimer's diseaseAlzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-002171-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002171-11.